PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24672126-2	2005	Lamotrigine as monotherapy or adjunctive therapy has been demonstrated to be effective in reducing the frequency of partial and generalized seizures in short- and long-term studies in children, adolescents, adults, and elderly patients with epilepsy, including those with JME.	Lamotrigine	0-11	myoclonic epilepsy, juvenile, 2	Homo sapiens	272-275	
24672126-3	2005	With its tolerability profile and spectrum of efficacy, lamotrigine might be an appropriate option for newly diagnosed patients with JME, a possibility that has not been empirically assessed.	Lamotrigine	56-67	myoclonic epilepsy, juvenile, 2	Homo sapiens	133-136	
24672126-4	2005	OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of lamotrigine monotherapy in patients with newly diagnosed JME.	Lamotrigine	80-91	myoclonic epilepsy, juvenile, 2	Homo sapiens	137-140	
24672126-15	2005	CONCLUSIONS: In this study, lamotrigine monotherapy given to patients with newly diagnosed JME was associated with a reduction in the frequency of seizures and improvement in global clinical status as rated by the investigators.	Lamotrigine	28-39	myoclonic epilepsy, juvenile, 2	Homo sapiens	91-94	
12925366-10	2003	CONCLUSIONS: Lamotrigine and topiramate are effective alternative options to valproic acid in the treatment of JME.	Lamotrigine	13-24	myoclonic epilepsy, juvenile, 2	Homo sapiens	111-114	
30747367-8	2019	However, lamotrigine may have the potential to aggravate JME, with promyoclonic effects.	Lamotrigine	9-20	myoclonic epilepsy, juvenile, 2	Homo sapiens	57-60	
30747367-12	2019	Patients with JME taking oral contraceptive should be counselled on the fact that the estrogenic component can reduce concentrations of lamotrigine by over 50%, putting patients at risk of increased seizures.	Lamotrigine	136-147	myoclonic epilepsy, juvenile, 2	Homo sapiens	14-17	
19863907-5	2009	We present a patient with JME who experienced myoclonic status epilepticus every months not controlled with lamotrigine monotherapy (200 mg/d), not controlled with levetiracetam monotherapy (1000 mg/d).	Lamotrigine	108-119	myoclonic epilepsy, juvenile, 2	Homo sapiens	26-29	
33421702-5	2021	All but two patients with paradoxical reactions to lamotrigine were diagnosed with juvenile myoclonic epilepsy (JME), otherwise, the clinical and electroencephalographic characteristics of patients with paradoxical reactions did not differ.	Lamotrigine	51-62	myoclonic epilepsy, juvenile, 2	Homo sapiens	112-115	
33421702-6	2021	At treatment start, the estimated risk of a paradoxical reaction to lamotrigine was 7.9 % in JME patients (n = 190).	Lamotrigine	68-79	myoclonic epilepsy, juvenile, 2	Homo sapiens	93-96	
33421702-8	2021	JME), the estimated risk of clinically relevant seizure aggravation under treatment with lamotrigine was 3.7 % (1.8 % for zonisamide and 0.8 % for levetiracetam).	Lamotrigine	89-100	myoclonic epilepsy, juvenile, 2	Homo sapiens	0-3	
33421702-9	2021	In conclusion, clinical significant aggravation of seizure frequency is common in lamotrigine-treated JME patients but rare in patients with other GGE subsyndromes or under treatment with other recommended anti-seizure medication.	Lamotrigine	82-93	myoclonic epilepsy, juvenile, 2	Homo sapiens	102-105	
26283305-3	2015	RESULTS: We identified three young adult women diagnosed with JME in their teenage years, with myoclonic, generalized tonic-clonic, and absence seizure semiologies, along with psychiatric comorbidity, well managed on lamotrigine and/or levetiracetam.	Lamotrigine	217-228	myoclonic epilepsy, juvenile, 2	Homo sapiens	62-65